MV-NiV

CEPI-Nipah

at a glance

TARGET DISEASE

Nipah virus Infection

TIMELINE

01 March 2019 to 31 March 2023

COORDINATOR

University of Tokyo with European Vaccine Initiative as co-leader

FUNDER

CEPI

FUNDING

10 Mio US$

SUMMARY

CEPI-Nipah

The CEPI-funded Nipah vaccine candidate is a live attenuated measles vector-based vaccine containing the Nipah-virus G gene (Malaysia strain). The recombinant vaccine candidate was developed at The Institute of Medical Science, University of Tokyo, and has shown to induce humoral and cellular responses in a preclinical study. In addition, the vaccine protected against lethal nipah virus infection in a hamster and non-human primate model. Process development and manufacturing is under development at Batavia Biosciences.

CEPI-Nipah

PARTNERS

Batavia Biosciences (Netherlands); European Vaccine Initiative (EVI) (Germany); University of Stanford (USA); University of Tokyo (Japan).

CEPI

This project has received funding from the Coalition for Epidemic Preparedness Innovations (CEPI).